Literature DB >> 6977569

The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.

P I Tarr, S W Hosea, E J Brown, R Schneerson, A Sutton, M M Frank.   

Abstract

Employing an in vitro bactericidal assay using C4-deficient guinea pig serum (C4D-GPS), we evaluated the ability of the alternative pathway to kill a number of strains of encapsulated and unencapsulated Haemophilus influenzae (HI). Complement activation occurred, but no bactericidal activity was observed against any of the tested HI in nonimmune C4D-GPS without detectable antibody to HI-type b (HIb) capsular polysaccharide (HIb-ps). In the presence of high-titered human anti- (type b) IgG, C4D-GPS killed the encapsulated strains. Restoration of classical pathway activity by the addition of purified C4 to C4D-GPS, which contained antibody to somatic antigens, resulted in killing of some strains of both encapsulated and unencapsulated HI. In nonimmune C4D-GPS the alternative pathway is activated but does not mediate bactericidal activity. The addition of specific high-titered anticapsular IgG results in killing of encapsulated HI by the alternative pathway in guinea pig serum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6977569

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

2.  Effect of amplification of the Cap b locus on complement-mediated bacteriolysis and opsonization of type b Haemophilus influenzae.

Authors:  G J Noel; A Brittingham; A A Granato; D M Mosser
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

3.  Arthropathic group A streptococcal cell walls require specific antibody for activation of human complement by both the classical and alternative pathways.

Authors:  R A Eisenberg; J H Schwab
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

4.  Multiple mechanisms in serum factor-induced resistance of Haemophilus influenzae type b to antibody.

Authors:  M Kuratana; E J Hansen; P Anderson
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

5.  Effect of complement depletion on anticapsular-antibody-mediated immunity to experimental infection with Haemophilus influenzae type b.

Authors:  J R Schreiber; C J Basker; G R Siber
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

6.  Serum IgG levels and complement activity in hypogammaglobulinaemic patients under substitution therapy.

Authors:  A Plebani; L D Notarangelo; M Duse; A Avanzini; M Massa; A G Ugazio
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

Review 7.  The role of complement in host resistance to bacteria.

Authors:  E J Brown; K A Joiner; M M Frank
Journal:  Springer Semin Immunopathol       Date:  1983

8.  Role of complement in mouse macrophage binding of Haemophilus influenzae type b.

Authors:  G J Noel; D M Mosser; P J Edelson
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

9.  Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway.

Authors:  S K Kochi; R C Johnson
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

10.  Generation of chemotactic activity in serum by Haemophilus influenzae type b.

Authors:  M F Tosi; S L Kaplan; E O Mason; G J Buffone; D C Anderson
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.